Core Viewpoint - The company is preparing to launch a first-class original new drug, Abanateptide, which has been featured in a promotional report by the "Changshan Metabolism" public account, along with interpretations from five top domestic diabetes experts [2]. Group 1 - The "Changshan Metabolism" WeChat public account is registered by the company's subsidiary, Changshan Kaijie Health Biotechnology (Beijing) Co., Ltd., focusing on the metabolism field and sharing academic information [2]. - The company encourages investors to follow the "Changshan Metabolism" public account for updates and information related to metabolic health [2].